| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Spongouridine is a nucleoside analog that has been found to possess various biological activities, including antitumor, antiviral, and antifungal properties. It suppresses the proliferation/growth of mouse lymphoma cells. Its mechanism of action is related to its structure as a nucleoside analog, which may interfere with nucleic acid synthesis. Spongouridine is a deamination metabolite of Cytarabine, an anticancer drug.
|
|---|---|
| ln Vitro |
In vitro, Spongouridine suppresses the proliferation/growth of mouse lymphoma cells. It has been found to have potent antitumor activity against various types of cancer cells, including breast, lung, and colon cancer cells. Its in vitro activity is characterized by antiproliferative effects against cancer cell lines. Spongouridine also exhibits antiviral and antifungal properties.
|
| ln Vivo |
In vivo, Spongouridine has been studied for its potential therapeutic applications. As a nucleoside analog, it may have antitumor, antiviral, and antifungal activities. However, detailed in vivo efficacy data for specific disease models are limited. Spongouridine is primarily used as a research tool for studying nucleoside analog biology and as an impurity of Cytarabine.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typical for Spongouridine, as it is a nucleoside analog that acts by interfering with nucleic acid synthesis rather than binding to specific enzymes or receptors. However, its effects on DNA and RNA synthesis can be studied using cell-free assays. These assays provide insights into its mechanism of action as a nucleoside analog.
|
| Cell Assay |
In vitro cellular assays for Spongouridine typically involve treating cancer cell lines with the compound and measuring cell viability and proliferation. The compound suppresses the proliferation/growth of mouse lymphoma cells and has potent antitumor activity against breast, lung, and colon cancer cells. These cell-based studies demonstrate its antiproliferative effects and its potential as an anticancer agent.
|
| Animal Protocol |
In vivo animal models for Spongouridine may include xenograft tumor models to evaluate its antitumor efficacy. However, detailed animal protocol information is limited. Spongouridine is primarily used as a research tool for studying nucleoside analog biology and as an impurity of Cytarabine. Its antiviral and antifungal properties may also be studied in appropriate animal models.
|
| ADME/Pharmacokinetics |
Spongouridine has a molecular formula of C9H12N2O6 and a molecular weight of 244.20. Its CAS number is 3083-77-0. The compound is also known as Uracil 1-β-D-arabinofuranoside, Arauridine, and 1-beta-D-Arabinofuranosyluracil. It is a deamination metabolite of Cytarabine and is used as an antiviral agent for the treatment of severe acute respiratory syndrome (SARS).
|
| Toxicity/Toxicokinetics |
Spongouridine is a nucleoside analog with a well-characterized mechanism of action. As with any nucleoside analog, potential toxicity may include effects on normal cell proliferation and nucleic acid synthesis. The compound's safety profile should be evaluated in preclinical toxicology studies. Spongouridine is for research use only and is not approved for human therapeutic use. It represents a valuable tool for studying nucleoside analog biology.
|
| References | |
| Additional Infomation |
Arauridine is an N-glycoside compound with metabolic activity. It has been reported in Lepisorus contortus and Eunicella cavolini, with relevant data available. It is a pyrimidine nucleoside formed in vivo from the deamination of cytarabine.
Spongouridine (CAS# 3083-77-0), also known as Uracil 1-β-D-arabinofuranoside or Ara-U, is a deamination metabolite of Cytarabine. It suppresses the proliferation/growth of mouse lymphoma cells and has potent antitumor activity against breast, lung, and colon cancer cells. Spongouridine has anti-inflammatory, pain relief, and vasodilatory properties. The compound is for research use only and not for human therapeutic use. |
| Molecular Formula |
C9H12N2O6
|
|---|---|
| Molecular Weight |
244.20138
|
| Exact Mass |
244.069
|
| CAS # |
3083-77-0
|
| PubChem CID |
18323
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Melting Point |
220-222ºC
|
| Index of Refraction |
1.643
|
| LogP |
-1.61
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
|
| InChi Key |
DRTQHJPVMGBUCF-CCXZUQQUSA-N
|
| InChi Code |
InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7+,8-/m1/s1
|
| Chemical Name |
1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~204.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.0950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
